Skip to content
Study details
Enrolling now

Combination Chemotherapy and Nelarabine for T-cell Acute Lymphoblastic Leukemia/Lymphoma

M.D. Anderson Cancer Center
NCT IDNCT00501826ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

160

Study length

about 19 years

Ages

All ages

Locations

1 site in TX

What this study is about

This trial is testing a treatment of combination chemotherapy with nelarabine to see how well it works in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. The treatment uses different drugs that stop cancer cell growth by killing, stopping division, or preventing spread.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cyclophosphamide
  • 2.Take Cytarabine
  • 3.Take Dexamethasone
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, dexamethasone, Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), mercaptopurine, methotrexate, nelarabine, pegaspargase

Drug routes

infusion, injection (Injection), injection, ocular, oral (Oral Tablet), oral

Endpoints

Primary: Complete remission rate, Overall survival, Progression-free survival

Body systems

Oncology